Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression

Zhang, Qinting; Wu, Hong; Li, Haozhe; Peng, Fanglan; Wang, Fan; Li, Ningning; Xiang, Hui; Zhang, Zongfeng; Su, Yousong; Huang, Yueqi; Zhang, Shengyu; Zhao, Guoqin; Zhou, Rubai; Mao, Ling; Lin, Zhiyun; Cai, Wei-Xiong; Fang, Yiru; Xie, Bin; Zhao, Min

doi:10.1016/j.ijpsycho.2017.02.001

Cited by 27 publications

(26 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-one schizophrenic patients who were hospitalized in Shanghai Mental Health Center, were enrolled in a study investigating the correlation between high-sensitivity CRP (hsCRP), interleukin-10 (IL-10) and clinical characteristics, particularly aggression, and their role as potential plasma biomarkers of schizophrenia [ 89 ]. Statistically significant higher levels of hsCRP (p<.001) and higher ratio of hsCRP and IL-10 were observed in the plasma of patients affected with schizophrenia, compared to healthy controls.…”

Section: Resultsmentioning

confidence: 99%

“…Statistically significant higher levels of hsCRP (p<.001) and higher ratio of hsCRP and IL-10 were observed in the plasma of patients affected with schizophrenia, compared to healthy controls. Furthermore, a positive correlation has been observed between hsCRP and the total score and verbal aggression score of the modified Overt Aggression Scale (MOAS) (p<.01) and between hsCRP/IL-10 and the total score of MOAS (p<.01) [ 89 ].…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, increased CRP levels have been reported amongst schizophrenics with catatonic features associated to the illness [ 63 ], with a comorbid metabolic syndrome [ 40 , 64 ], in acutely agitated schizophrenics with an increased cardiovascular risk [ 81 ], negative symptomatology [ 55 , 67 ], with a low quality of life [ 72 ], a greater physical functional impairment [ 82 ], and a higher mortality [ 86 ], amongst schizophrenia subjects. Furthermore, an association has been as well reported between elevated CRP levels and more aggressive schizophrenics [ 77 , 89 ], but not with suicidal behaviour [ 77 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, there are several major limitations in the present review that should be acknowledged. First, most studies own methodological dis-homogeneities, such as inclusion/exclusion criteria (not all studies included only schizophrenic patients), different sample size (some of them included a small sample size with different clinical features) [ 40 , 62 , 64 , 67 , 71 , 76 , 77 , 79 , 80 - 84 , 89 , 92 ], various recruitment settings ( i.e ., inpatients, outpatients, community-based sample, etc .) and study design (Table 1 ).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review

Orsolini

Sarchione

Vellante

et al. 2018

View full text Add to dashboard Cite

BackgroundSchizophrenia is a complex illness in which genetic, environmental, and epigenetic components have been implicated. However, recently, psychiatric disorders appear to be related to a chronic inflammatory state, at the level of specific cerebral areas which have been found as well impaired and responsible for schizophrenia symptomatology. Hence, a role of inflammatory mediators and cytokines has been as well defined. Accordingly, the role of an acute inflammatory phase protein, the C-reactive protein (CRP) has been recently investigated.ObjectiveThe objective of the present study is to evaluate how PCR may represent a biomarker in schizophrenia, i.e. correlated with illness phases and/or clinical manifestation and/or psychopathological severity.MethodsA systematic review was here carried out by searching the following keywords ((C-reactive protein AND ((schizophrenia) OR (psychotic disorder))) for the topics ‘PCR’ and ‘Schizophrenia’, by using MESH terms.ResultsAn immune dysfunction and inflammation have been described amongst schizophrenic patients. Findings reported elevated CRP levels in schizophrenia, mainly correlated with the severity of illness and during the recrudescent phase. CRP levels are higher when catatonic features, negative symptomatology and aggressiveness are associated. CRP levels appeared not to be related to suicidal behaviour and ideation.ConclusionCRP and its blood levels have been reported higher amongst schizophrenic patients, by suggesting a role of inflammation in the pathogenesis of schizophrenia. Further studies are needed to better understand if CRP may be considered a biomarker in schizophrenia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review

Orsolini

Sarchione

Vellante

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Metcalf et al reported that individuals with high (> 3 mg/L) compared with low (< 1 mg/L) CRP levels at baseline were more likely to develop SZ (adjusted odd ratio 4.25, 95% CI, 1.30 to 13.93) [ 55 ]. Zhang et al found that high sensitivity CRP/ interleukin-10 was a potential peripheral biomarker of SZ [ 56 ].…”

Section: Introductionmentioning

confidence: 99%

Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis

Wang

Chi

et al. 2017

Oncotarget

View full text Add to dashboard Cite

C-reactive protein (CRP) has been indicated to be associated with the pathogenesis of schizophrenia (SZ) and other psychiatric disorders. The aim of this study is to investigate whether peripheral blood CRP levels are associated with the risk of SZ. We searched literature from databases of Pubmed, Embase and the Cochrane Library from inception to November 1, 2016 for studies that reported serum or plasma CRP levels in patients with SZ and non-SZ controls. At least two reviewers decided on eligibility and extracted data from included studies. Random effects meta-analyses were performed using standardized mean difference (SMD) as the effect estimate of the differences in CRP levels between subjects with SZ and healthy controls. We identified 18 studies representing 1963 patients with SZ and 3683 non-SZ controls. Compared with non-schizophrenics, blood CRP levels were moderately increased in people with SZ (SMD 0.53, 95% CI 0.30 to 0.76) irrespective of study region, sample size of included studies, patient mean age, age of SZ onset and patient body mass index. Publication bias was not detected through Egger's linear regression test (P = 0.292). We noticed that patients in Asia or Africa (n = 6, SMD 0.73, 95% CI 0.26 to 1.21) and whose age less than 30 years (n = 5, SMD 0.76, 95% CI 0.07 to 1.58) had substantially higher CRP levels. Our study provides evidence that higher CRP levels are associated with increased risk of SZ, especially for young adult patients less than 30 years. Further large-scale studies are strongly warranted to further confirm this association.

show abstract

Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification

Pratt

Morris

Dawson

2018

Current Topics in Behavioral Neurosciences

View full text Add to dashboard Cite

Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

show abstract

Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression

Cited by 27 publications

References 47 publications

Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review

Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review

Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis

Deconstructing Schizophrenia: Advances in Preclinical Models for Biomarker Identification

Contact Info

Product

Resources

About